TScan Therapeutics May 2025 slides: advancing TCR-T therapies with positive Phase 1 data

Introduction & Market Context

TScan Therapeutics presented its corporate overview on May 6, 2025, highlighting its clinical-stage pipeline of T-cell receptor (TCR) therapies for both hematologic malignancies and solid tumors. The company is developing novel immunotherapies that aim to address limitations of current approaches like CAR-T and checkpoint inhibitors, particularly in treating solid tumors and preventing relapse after hematopoietic cell transplantation.

As shown in the following overview slide, TScan has built a diverse pipeline targeting multiple HLA types with several upcoming catalysts expected by the end of 2025:

Executive Summary

TScan’s presentation focused on two main programs: its hematologic malignancies (HEME) program, which has shown promising Phase 1 data, and its solid tumor program utilizing a multiplex approach. The company highlighted its strong financial position with $290.1 million in cash as of December 31, 2024, providing runway into Q1 2027.

The company’s approach differs from competitors by targeting six different HLA types, compared to most companies that only target one (A02:01), allowing TScan to address a broader patient population. This strategy is illustrated in their comparative analysis of immunotherapy approaches:

ALLOHA Phase 1 Trial Results

The presentation devoted significant attention to results from the ALLOHA Phase 1 trial, which evaluated TSC-100 and TSC-101 in patients with AML, ALL, and MDS who underwent allogeneic hematopoietic cell transplantation (HCT). The trial demonstrated that TScan’s TCR-T cells persisted for over a year after infusion, with increased persistence observed at the highest dose level:

Most importantly, the trial showed promising efficacy data with lower relapse rates in the treatment arm compared to the control arm. As shown in the following Kaplan-Meier plot, only 8% (2 of 26) of patients in the treatment arm relapsed versus 33% (4 of 12) in the control arm:

The event-free survival data similarly favored the treatment arm, with a hazard ratio of 0.30. Only 23% (6 of 26) of patients in the treatment arm experienced an event compared to 58% (7 of 12) in the control arm:

The company summarized the key findings from the ALLOHA trial, emphasizing that the TCR-T cell infusions were well-tolerated, with cells persisting for over a year and showing a clear dose-persistence relationship:

Pivotal Trial Plans for Heme Program

Based on the positive Phase 1 results, TScan is planning a pivotal study for TSC-101, which will compare the treatment to a synthetic control arm based on CIBMTR registry data. The primary endpoint will be relapse-free survival, with overall survival as a key secondary endpoint:

The company also highlighted the expanding addressable market for its heme program, noting that increased use of haploidentical (Haplo) and mismatched unrelated donors (MMUD) will continue to grow the potential patient population:

Looking further ahead, TScan outlined expansion opportunities to reach over 10,000 patients through additional HLA types, transplant expansion, and disease expansion:

Solid Tumor Program Strategy

For solid tumors, TScan is developing a multiplex TCR-T therapy approach to address tumor heterogeneity. The company presented data showing that solid tumors often have heterogeneous antigen expression, which can lead to treatment resistance with single-target approaches.

The PLEXI-T multi-arm basket Phase 1 trial is currently ongoing, evaluating TScan’s solid tumor candidates across multiple tumor types including non-small cell lung cancer, sarcoma, head and neck cancer, cervical cancer, and anal and genital cancers.

TScan is building what it calls an "ImmunoBank" of TCRs to enable customized, multiplex TCR-T therapy based on individual patient tumor profiles. This approach aims to increase the percentage of patients eligible for treatment across various cancer types.

Financial Position and Outlook

TScan reported a strong financial position with $290.1 million in cash as of December 31, 2024, which is expected to fund operations into Q1 2027. The company has 129.7 million total economic shares outstanding as of the same date.

The company’s near-term catalysts include launching a pivotal study for the HEME program in the second half of 2025 and presenting safety and response data for the SOLID TUMOR program in the same timeframe.

Forward-Looking Statements

TScan’s presentation highlighted several forward-looking milestones, including the pivotal study for TSC-101 with topline readout expected in the second half of 2027. The company estimates a $1 billion addressable market across the US and EU for its heme program.

For the solid tumor program, TScan is focused on advancing its multiplex approach to address key indications with significant unmet needs, including non-small cell lung cancer, which represents an estimated 63,000 patients in the US alone.

As the company progresses both programs, its in-house GMP manufacturing capabilities will be a key asset in supporting clinical trials and potential commercial production.

Full presentation:

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.